v3.26.1
Segment Information - Summary of Selected Financial Information with Respect to Single Operating Segment (Detail) - USD ($)
8 Months Ended 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Apr. 30, 2025
Apr. 30, 2024
Segment expenses and other segment items        
Total revenues $ 49,078,000      
Cost of revenue 3,081,000      
Clinical development 14,723,000   $ 43,166,000 $ 46,520,000
Research 12,851,000   19,713,000 36,074,000
Regulatory & QA 5,239,000   8,830,000 3,573,000
Commercial 89,441,000   62,859,000 18,481,000
Other SG&A 35,780,000   53,427,000 35,797,000
Other income 1,480,000 $ 6,576,000 7,943,000 13,801,000
Income tax expense (benefit) (1,033,000)   3,392,000 0
Segment net loss (109,524,000)   (183,444,000) (126,644,000)
Reconciliation of segment profit or loss:        
Adjustments and reconciling items 0   0 0
Consolidated net loss $ (109,524,000) $ (110,454,000) $ (183,444,000) $ (126,644,000)